Blackstone Inc.: Q3 Earnings Snapshot

Blackstone Inc. (BX) reported Q3 earnings of $662.4 million, or $1.32 per share adjusted, beating analyst estimates. Revenue was $3.06 billion, with adjusted revenue at $3.22 billion, also surpassing forecasts. Shares have fallen 29% year-to-date.

Original reporting
Published Oct 22, 2026, 11:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 11:21 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Blackstone Inc.: Q3 Earnings Snapshot — source image
Decision brief

The 30-second read

$BXBullishHigh
01

Why it matters

The earnings beat could prompt short covering and modest buying, but broader market sentiment may temper gains.

02

Market read

Earnings surprise provides a short‑term trading catalyst for BX and may influence sentiment toward the private‑equity sector.

03

What to watch

Potential concerns about future fundraising environment and macro‑economic headwinds.

Relevance 8/10Novelty 8/10Timing: after-market release

Background

Blackstone is a leading global investment manager; its earnings are closely watched for insights into alternative asset performance.

Company-level read

Ticker impact

$BXBullishHigh confidence
Context

Blackstone Inc. reported Q3 earnings of $662.4M, EPS $0.83, adjusted EPS $1.32, beating Zacks estimates.

Expected impact

likely modest upside as market prices in the earnings beat

Evidence & confidence

Beat on both earnings and revenue, with adjusted figures above expectations, suggests better-than-expected performance.

Market effects

Private‑equity sector may see a lift as Blackstone's beat suggests resilience in fee‑related earnings.

U.S. markets may see a modest rally in financials following the surprise.

Limited to investors tracking large‑cap alternative asset managers.

Counterpoint

Shares have fallen 29% YTD; the beat may be priced in, limiting upside.

Key entities

  • Blackstone Inc.

    Global investment manager reporting Q3 results.

Related articles

$BXHigh

Blackstone's 16% Stake In IIFL Finance To Strengthen Capital Base

Blackstone Inc. plans to acquire a 16% stake in IIFL Finance, investing Rs 5,000 crore to boost its capital base. Fitch Ratings expects this to double IIFL Finance's Tier 1 capital ratio to 25.7% by September 2026, enhancing its funding flexibility and supporting growth plans. The transaction is not expected to immediately impact IIFL Finance's ratings or business model, which focuses on secured lending.

$PFEMedAI 8/10

Your Questions Answered: GLP-1 Deals, FDA Approvals, and Manufacturing Buildout

Pfizer and Blackstone Life Sciences agreed to co-fund berobenatide, a GLP-1 drug for weight management, with Blackstone covering up to $1.5B in development costs. Pfizer retains control. J&J acquired Ollin Biosciences for $2.2B, Lilly acquired Calytrix Bio for up to $1.5B, and Sanofi partnered with Seawolf Therapeutics. Gilead licensed obeldesivir to generic manufacturers for Ebola prevention. The FDA approved Novartis' Cosentyx for polymyalgia rheumatica and Roche's Wilserdly for breast cancer.